|
2026
|
P/S
|
Produits pharmaceutiques; médicaments pour la médecine humaine; préparations pharmaceutiques à us... |
|
|
P/S
|
Pharmaceuticals; Medicines for human purposes; Pharmaceutical preparations for veterinary use; Ch... |
|
|
P/S
|
Pharmaceutical products; medicines for human purposes;
pharmaceutical preparations for veterinar... |
|
|
Invention
|
Method of making lanifibranor.
The present disclosure relates to a process for manufacturing lan... |
|
|
P/S
|
Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharm... |
|
|
P/S
|
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations;... |
|
2025
|
P/S
|
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines ... |
|
|
P/S
|
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical... |
|
|
Invention
|
Synthesis of lanifibranor. The present disclosure is directed to a process for preparing lanifibr... |
|
|
Invention
|
Amino-alcohol compounds and their use in therapy. 123,4,5,5,6,6, 7,899 are as defined herein. The... |
|
|
Invention
|
Azetidine compounds and their use in therapy. 1,2,3,4,5,6,6,7,899 are as defined herein. The comp... |
|
|
Invention
|
Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in ... |
|
|
Invention
|
Non-invasive monitoring of nash treatment with lanifibranor. in vitroin vitro measuring levels of... |
|
|
Invention
|
Treatment of a liver disease in patients with hepatic impairment. The present invention relates t... |
|
|
Invention
|
Deuterated derivatives of lanifibranor.
The present invention relates to a deuterated derivative... |
|
|
Invention
|
Methods and monitoring of treatment with lanifibranor.
The present disclosure relates to methods... |
|
|
Invention
|
Prevention of blood disorders in patient treated with a ppar agonist. The present invention relat... |
|
|
Invention
|
Pyrrolopyrazine compounds and their use in therapy. 11111 are as defined in the description, to p... |
|
|
P/S
|
Pharmaceutical products; medicines for human medicine;
antibiotics; pharmaceutical preparations;... |
|
2024
|
Invention
|
Combination therapy for the prevention and/or the treatment of a liver disease. The present discl... |
|
|
Invention
|
Non-invasive monitoring of nash treatment with lanifibranor. The present disclosure relates to a ... |
|
|
Invention
|
Method of making lanifibranor |
|
|
Invention
|
Method of making lanifibranor. The present disclosure relates to a process for manufacturing lani... |
|
|
Invention
|
Synthesis of lanifibranor intermediate |
|
|
Invention
|
Synthesis of lanifibranor intermediate. The present disclosure is directed to a process for prepa... |
|
|
Invention
|
Non-invasive monitoring of liver disease treatment.
The present disclosure relates to a method o... |
|
|
Invention
|
Non-invasive monitoring of liver disease treatment.
The present disclosure relates to a method f... |
|
|
Invention
|
Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver cond... |
|
|
Invention
|
Methods and monitoring of treatment with lanifibranor. The present invention relates to methods f... |
|
|
P/S
|
Pharmaceutical and veterinary preparations; Chemical preparations for medical or pharmaceutical p... |
|
|
Invention
|
Lanifibranor formulation |
|
|
Invention
|
Lanifibranor formulation. The present invention is directed to a pharmaceutical composition usefu... |
|
2023
|
Invention
|
Crystal form of lanifibranor, preparation method therefor, and use thereof. Provided are novel cr... |
|
|
Invention
|
Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment w... |
|
|
Invention
|
Use of adiponectin, ferritin, mmp9 and transferrin for monitoring liver disease treatment with la... |
|
|
Invention
|
Crystalline form of lanifibranor.
The present invention relates to a crystalline form of lanifib... |
|
|
Invention
|
Crystalline form of lanifibranor. The present invention relates to a crystalline form of lanifibr... |
|
2022
|
Invention
|
Crystal form of lanifibranor, preparation method therefor, and use thereof.
Provided are novel c... |
|
2021
|
Invention
|
Combination therapy for the treatment of a liver disease.
The invention relates to a drug combin... |
|
|
Invention
|
Combination therapy for the treatment of a liver disease. The invention relates to a drug combina... |
|
2019
|
Invention
|
Method of treatment of cirrhosis. The invention relates to a method of treating cirrhosis which c... |
|
|
Invention
|
A method of treatment of cirrhosis. The invention relates to a method of treating cirrhosis which... |
|
|
Invention
|
Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer. The inventio... |
|
|
Invention
|
Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer. A compound o... |
|
|
Invention
|
Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer. 123455 and f... |
|
|
Invention
|
Deuterated derivatives of lanifibranor. The present invention relates to deuterated derivatives o... |
|
|
P/S
|
Préparations chimiques destinées à la fabrication de produits pharmaceutiques; ces produits n'éta... |
|
|
P/S
|
Pharmaceutical and veterinary products, namely, pharmaceutical preparations for the treatment of ... |
|
|
P/S
|
Pharmaceutical and veterinary products; chemical
preparations for medical or pharmaceutical use. |
|
2018
|
P/S
|
Printed matter, periodicals, magazines (periodicals),
posters, brochures, prospectuses, printed ... |
|
|
Invention
|
Ppar compounds for use in the treatment of fibrotic diseases. The invention relates to the use of... |
|
|
Invention
|
New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malig... |
